This is a repository copy of Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/145620/

Version: Published Version

**Article:**
Robertson, Lindsay, Mcbride, Olivia and Burdess, Anne (2016) Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis. Cochrane Database of Systematic Reviews. CD011536. pp. 1-18. ISSN 1469-493X

https://doi.org/10.1002/14651858.CD011536.pub2

---

**Reuse**
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis (Review)

Robertson L, McBride O, Burdess A

Robertson L, McBride O, Burdess A.
Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis.
DOI: 10.1002/14651858.CD011536.pub2.

www.cochranelibrary.com
# Table of Contents

- **HEADER** .......................................................... 1
- **ABSTRACT** ......................................................... 1
- **PLAIN LANGUAGE SUMMARY** ...................................... 2
- **BACKGROUND** ....................................................... 2
- **OBJECTIVES** ........................................................ 4
- **METHODS** .......................................................... 4
- **RESULTS** ............................................................ 6
  - Figure 1 .................................................................. 7
- **DISCUSSION** .......................................................... 8
- **AUTHORS' CONCLUSIONS** .......................................... 9
- **ACKNOWLEDGEMENTS** .............................................. 9
- **REFERENCES** .......................................................... 9
- **CHARACTERISTICS OF STUDIES** ................................. 11
- **DATA AND ANALYSES** .............................................. 14
- **APPENDICES** .......................................................... 14
- **CONTRIBUTIONS OF AUTHORS** ................................... 15
- **DECLARATIONS OF INTEREST** .................................... 15
- **SOURCES OF SUPPORT** .............................................. 16
- **INDEX TERMS** ........................................................ 16
Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis

Lindsay Robertson1, Olivia McBride2, Anne Burdess2

1Department of Vascular Surgery, Freeman Hospital, Newcastle upon Tyne, UK. 2Department of Vascular Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK

Contact address: Lindsay Robertson, Department of Vascular Surgery, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, High Heaton, Newcastle upon Tyne, NE7 7DN, UK. lindsay.robertson@nuth.nhs.uk, lindsay.robertson@ed.ac.uk.

Editorial group: Cochrane Vascular Group.


Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Deep venous thrombosis (DVT) occurs in approximately one in 1000 adults every year, and has an annual mortality of 14.6%. In particular, iliofemoral DVT can lead to recurrent thrombosis and post-thrombotic syndrome (PTS), a painful condition which can lead to chronic venous insufficiency, oedema, and ulceration. It causes significant disability, impaired quality of life, and economic burden. Early thrombus removal techniques have been advocated in patients with an iliofemoral DVT in order to improve vein patency, prevent valvular dysfunction, and reduce future complications, such as post-thrombotic syndrome and venous ulceration. One such technique is pharmacomechanical thrombectomy, a combination of catheter-based thrombectomy and catheter-directed thrombolysis.

Objectives

To assess the effects of pharmacomechanical thrombectomy versus anticoagulation (alone or with compression stockings), mechanical thrombectomy, thrombolysis, or other endovascular techniques in the management of people with acute DVT of the iliofemoral vein.

Search methods

The Cochrane Vascular Information Specialist searched the Specialised Register (last searched December 2015) and the Cochrane Register of Studies (last searched December 2015). We searched clinical trials databases for details of ongoing or unpublished studies and the reference lists of relevant articles retrieved by electronic searches for additional citations.

Selection criteria

Randomised controlled trials in which patients with an iliofemoral deep vein thrombosis were allocated to receive pharmacomechanical thrombectomy versus anticoagulation, mechanical thrombectomy, thrombolysis (systemic or catheter directed thrombolysis), or other endovascular techniques for the treatment of iliofemoral DVT.

Data collection and analysis

At least two review authors independently assessed studies identified for potential inclusion.

Main results

We found no randomised controlled trials that met the eligibility criteria for this review. We identified one ongoing study.
Authors’ conclusions

There were no randomised controlled trials that assessed the effects of pharmacomechanical thrombectomy versus anticoagulation (alone or with compression stockings), mechanical thrombectomy, thrombolysis, or other endovascular techniques in the management of people with acute DVT of the iliofemoral vein that met the eligibility criteria for this review. Further high quality randomised controlled trials are needed.

Plain Language Summary

Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis

Background

Deep vein thrombosis (DVT) is a condition in which a blood clot forms in the deep vein of the leg or pelvis. It affects approximately 1 in 1000 people. If it is not treated, the clot can travel in the blood, and block the arteries in the lungs. This life-threatening condition is called a pulmonary embolism and occurs in approximately 3 to 4 in 10,000 people. Another side-effect of DVT is post-thrombotic syndrome (PTS), a condition in which the patient suffers pain, swelling, and changes in the skin of the leg, which can lead to an ulcer. This causes significant disability and diminished quality of life, and is costly to the healthcare system.

One way to prevent another blood clot or PTS is to remove the clot. There are a number of ways to do this. A catheter can be inserted into the vein and the clot removed directly (mechanical thrombectomy), the clot can be broken down through the use of drugs infused into a vein in the foot or directly at the site of the clot using a catheter and X-ray control (pharmacomechanical thrombolysis), or a combination of the two procedures. This review aimed to measure how safe and effective pharmacomechanical thrombectomy is, compared to other techniques.

Key results

There were no randomised controlled trials that met the inclusion criteria of this review (current until December 2015). We identified one ongoing study.

Quality of evidence

At present, there is a lack of randomised controlled trials that examine the comparative effectiveness and safety of pharmacomechanical thrombectomy in the management of patients with DVT.

Conclusion

Further research is required before conclusions can be made.

Background

Description of the condition

Deep vein thrombosis (DVT) is a condition in which a blood clot forms in the deep vein of the leg or pelvis. It is a common condition, resulting in significant morbidity and mortality. Deep vein thrombosis occurs in approximately one in 1000 adults annually (White 2003), and has an associated one year mortality of 14.6% (Ageno 2006). In particular, untreated proximal DVT or iliofemoral DVT carries an approximate 50% risk of developing into a symptomatic pulmonary embolism within three months, 10% of which carries a risk of mortality within one hour of symptom onset (Kearon 2003). A major cause of DVT-related morbidity is post-thrombotic syndrome (PTS), which is characterised by pain, chronic venous insufficiency, oedema, and associated skin changes, and can progress to venous ulceration, despite conventional treatment. Post-thrombotic syndrome typically occurs within two years of a DVT, and is reported to occur in around 30% to 60% of patients, with 10% suffering from severe PTS (Prandoni 2009). It causes
significant disability, impaired quality of life and economic burden (Access Economics Pty Limited 2008).

Deep vein thrombosis can be divided anatomically, into proximal DVT, affecting either the iliofemoral or femoral vein and distal DVT, affecting the popliteal vein or more distally (Jenkins 2011). Iliofemoral DVT occludes both draining venous systems of the lower limb, that of the femoral vein and the superficial femoral vein, so there is decreased room for collateralisation of venous drainage (Jenkins 2011). Consequently, iliofemoral DVT has an increased propensity for complications such as pulmonary embolism and PTS, compared to popliteal DVT.

Standard treatment of DVT currently involves immediate intravenous anticoagulation with unfractionated heparin, or more recently, with the use of low molecular weight heparin (Merli 2008). Early ambulation and graduated compression stockings (30 mmHg to 40 mmHg) are also standard treatment and have been shown to be particularly effective in preventing the development of PTS (Musani 2010). A meta-analysis indicated a 0.54 relative risk reduction in PTS with the use of graduated compression stockings post-DVT (Musani 2010). A randomised controlled trial by Prandoni 2004 determined that the incidence of PTS in the control group versus the elastic stockings group was 40.0% versus 21.1% after six months, 46.7% versus 22.2% after one year, and 49.1% versus 24.5% after two years. However, the SOX trial, a randomised placebo-controlled trial, showed that stockings offered no benefit in the prevention of PTS (Kahn 2014).

The goal of this current treatment strategy is to prevent thrombus propagation, embolisation, and recurrence of venous thromboembolism during both the early and later course of the disease. However, anticoagulation lacks fibrinolytic activity, so there is no attempt to remove or reduce existing thrombus load. In ultrasound based studies, complete resolution of DVT at one year was only around 50% (Kearon 2003). Furthermore, the one-year incidence of PTS is around 25% following first-time DVT, despite treatment with anticoagulation and elastic compression bandages (Pappy 2010).

Iliofemoral DVT in particular, carries a significant risk of both PTS and recurrent venous thromboembolism. Therefore, early thrombus removal techniques have been advocated in these select patient groups, in order to improve vein patency, preventing valvular dysfunction, and reduce future complications, such as PTS and venous ulceration.

Description of the intervention

Mechanical thrombectomy

Thrombectomy for DVT can be performed through either an open surgical approach or a percutaneous endovascular approach. Open thrombectomy is reserved for life- or limb-threatening DVT, and is seldom used, as it is much more invasive than endovascular techniques, and is associated with a disproportionately high incidence of rethrombosis (Suwanabol 2013).

Percutaneous mechanical thrombectomy modalities are a relatively new intervention available for treating DVT (Jenkins 2011). A number of different percutaneous devices exist, however, they all reduce clot burden through either suction, rotation, rheolysis, ultrasound, or a combination there-of.

Pharmacological thrombolysis

Thrombolysis has been used as a technique to remove clot burden, and can either be performed systemically, or locally in a procedure called catheter-directed thrombolysis (Jenkins 2011). Systemic thrombolysis has been shown to enhance clot removal and prevent propagation of thrombosis. However, it carries an increased risk of major bleeding episodes, and therefore, is rarely used in the setting of an acute DVT. Catheter-directed thrombolysis is a percutaneous technique involving the delivery of thrombolytics by an infusion catheter, directly to the venous thrombus, which allows clot lysis, whilst avoiding the major bleeding risks associated with systemic thrombolysis. Randomised controlled trials have demonstrated the feasibility and effectiveness of the technique in reducing PTS whilst minimising major bleeding risks to 1.7%, compared to 2% in the use of anticoagulation-only groups (Enden 2009; Watson 2014).

Pharmacomechanical thrombectomy

Some medical devices combine the use of both percutaneous mechanical thrombectomy and thrombolysis, using the same endovascular techniques. This combination of catheter-based thrombectomy and catheter-directed thrombolysis is referred to as pharmacomechanical thrombectomy. Pharmacomechanical thrombectomy, when compared to catheter-directed thrombolysis alone, has been shown to result in similar levels of clot removal, but with significant reduction in use of hospital resources, catheterisation, infusion time, and total dose of thrombolytic, hence, potentially reducing adverse bleeding events as well (Jenkins 2011).

Percutaneous endovenous intervention refers to a variety of endovascular techniques used for thrombus removal. It includes any one or more endovascular techniques, such as thrombectomy, balloon venoplasty, stenting, and low-dose thrombolysis, and has been shown to reduce DVT and PTS recurrence (TORPEDO 2012).
In addition, mechanical thrombectomy facilitates a more rapid removal of the thrombus, improving venous patency, decreasing venous hypertension, and ultimately, preventing valvular dysfunction and the development of PTS (Suwanabol 2013). Combining both mechanical thrombectomy with thrombolysis in pharmacomechanical thrombectomy can reduce the required dose of thrombolytic agent used compared to a thrombolytic technique alone, reducing the bleeding risks associated with either catheter-directed thrombolysis or systemic thrombolysis, whilst conferring the immediate benefits of a mechanical reduction in clot load (Jenkins 2011).

**Why it is important to do this review**

In addition to anticoagulation, thrombectomy, catheter-directed thrombolysis and pharmacomechanical thrombectomy are used as techniques to prevent thrombus propagation and thrombus removal, and to decrease the risk of both pulmonary embolism and PTS (Jenkins 2011). This review examined the evidence supporting the use of pharmacomechanical thrombectomy for iliofemoral DVT.

**OBJECTIVES**

To assess the effects of pharmacomechanical thrombectomy versus anticoagulation (alone or with compression stockings), mechanical thrombectomy, thrombolysis, or other endovascular techniques in the management of people with acute deep vein thrombosis of the iliofemoral vein.

**METHODS**

**Criteria for considering studies for this review**

**Types of studies**

We considered randomised controlled trials (RCTs) that compared pharmacomechanical thrombectomy versus anticoagulation (alone or in combination with compression stockings), mechanical thrombectomy, thrombolysis (systemic or catheter-directed thrombolysis), or other endovascular techniques for the treatment of iliofemoral deep vein thrombosis (DVT).

**Types of participants**

We included patients of all ages with DVT confirmed by objective testing, such as venography or duplex ultrasonography. We only considered DVTs at the iliofemoral level. We excluded patients with recurrent venous thromboembolism (VTE) or post-thrombotic syndrome (PTS), and those with treatment commencing after 21 days. If we were unable to clarify the anatomical level of DVT after interrogation of the data in a study, we did not use the results in our data analysis.

**Types of interventions**

We included any pharmacomechanical thrombectomy, defined as a combination of locally delivered thrombolytic agent used in conjunction with mechanical thrombectomy. Patients who received any type of thrombolysis or thrombectomy intervention also received standard DVT management, which included anticoagulation and the use of compression stockings. We considered the following comparisons:

- pharmacomechanical thrombectomy versus anticoagulation alone;
- pharmacomechanical thrombectomy versus anticoagulation and compression stocking use;
- pharmacomechanical thrombectomy versus mechanical thrombectomy;
- pharmacomechanical thrombectomy versus thrombolysis;
- pharmacomechanical thrombectomy versus other endovascular techniques (including balloon venoplasty and stenting).

**Types of outcome measures**

For all outcomes, we had planned to collect data for an early (up to one month), intermediate (one month to two years), and a long-term period (more than two years).

**Primary outcomes**

1. Post-thrombotic syndrome: (including venous ulceration rates, as defined by the Villalta scale; Prandoni 1992)
2. Any improvement in venous patency (assessed by objective measures, such as venography, where pre- and post-comparative data on the degree of restoration of the lumen were available)
3. Major bleeding (as defined by the International Society on Thrombosis and Haemostasis (ISTH); Schulman 2005):
   i) Fatal bleeding
   ii) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome
   iii) Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells.
iv) Any combination of points a to c

**Secondary outcomes**

1. Recurrent DVT
2. Pulmonary embolism
3. Mortality (all cause and pulmonary embolism-related)
4. Stroke, in particular, haemorrhagic stroke (preferably documented by objective means such as a computerised tomography (CT) scan or autopsy)
5. Venous function (assessed by duplex ultrasound or other objective means, such as foot volumetry or ambulatory venous pressure measurements)
6. Time in hospital
7. Quality of life

**Search methods for identification of studies**

**Electronic searches**

The Cochrane Vascular Information Specialist (CIS) searched the following databases for relevant trials:

- The Cochrane Vascular Specialised Register (December 2015);
- The Cochrane Central Register of Controlled Trials (CENTRAL (2015, Issue 11)) via The Cochrane Register of Studies Online.

See Appendix 1 for details of the search strategy used to search CENTRAL.

The Cochrane Vascular Specialised Register is maintained by the CIS and is constructed from weekly electronic searches of MEDLINE Ovid, Embase Ovid, CINAHL, AMED, and through hand-searching relevant journals. The full list of the databases, journals, and conference proceedings that have been searched, and the search strategies used, are described in the Specialised Register section of the Cochrane Vascular module in the Cochrane Library (www.cochranelibrary.com).

The CIS also searched the following trial databases for details of ongoing and unpublished studies, using the terms thrombectomy and thrombosis:

- World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Portal (apps.who.int/trialsearch/);
- ClinicalTrials.gov (clinicaltrials.gov/);
- ISRCTN Register (www.isrctn.com)

**Searching other resources**

We searched citations within identified studies. We also contacted authors of relevant papers by email, to identify any unpublished RCTs.

**Data collection and analysis**

**Selection of studies**

Two review authors (LR and AB or OM) independently reviewed the results of all searches and identified any article that was eligible, given a reference to thrombectomy for DVT. The two review authors discussed each study to confirm eligibility for inclusion in the systematic review; those that did not fulfil the criteria as described in Criteria for considering studies for this review were excluded, and the reasons for exclusion were described in the review. Disagreements were resolved by consensus.

**Data extraction and management**

Two review authors (LR, AB) had intended to independently extract from each study, information about the study characteristics, participants, interventions, duration of follow-up, and outcome parameters, using standardised forms. Where available, we had intended to extract data on the following items:

1. Study design.
2. Quality items.
3. Number of study patients.
4. Participants, including: age, sex, length of clot, diagnosis (clinical or ultrasound), presence of pulmonary embolism prior to treatment, presence of phlegmasia, and co-morbidities.
5. Interventions, including: thrombectomy device used, adverse events (major and minor), dose and delivery of thrombolytics, length of stay in hospital, and veins treated.
6. Outcome measures, including: PTS, venous patency and valve competency, major bleeding, recurrent DVT, pulmonary embolism, mortality, stroke, venous function, time in hospital, and quality of life.
7. Length of follow-up.

**Assessment of risk of bias in included studies**

Two review authors (LR, AB) had intended to independently assess the design and execution of each study according to the following criteria: random sequence generation, allocation concealment of treatment, blinding of participants, personnel, and outcomes, incomplete outcome data, selective outcome reporting, and other sources of bias in accordance with Cochrane’s tool for assessing risk of bias (Higgins 2011). We had intended to judge the studies as either low risk of bias, high risk of bias or, unclear (due to either lack of information or uncertainty over the potential for bias). We had planned to resolve disagreements by consensus between the two review authors, and involve a third review author (OM) if necessary.
Measures of treatment effect
We had intended to assess dichotomous data using risk ratio (RRs) with 95% confidence intervals (CIs). We had planned to analyse continuous outcomes using mean difference (MDs) with 95% CIs where the scales were the same, and where scales were different but outcome measured was the same, we had planned to use the standardised mean difference (SMD) with 95% CIs.

Unit of analysis issues
We did not include cross-over trials. The individual patient was the unit of the analysis.

Dealing with missing data
Where information was missing, we had planned to contact the authors of the relevant study. If unsuccessful, we had intended to exclude the data from the meta-analysis, but report it in the review. We had planned to include outcome measures only if it had been the intention of the study authors to perform the necessary assessments in all randomised patients. If less than 50% of the patients in a study had an acceptable follow-up for a particular outcome measure, due to the associated high risk of attrition bias, we had planned to not report the results of this outcome measure.

Assessment of heterogeneity
If the included studies were comparable with regard to age, sex, treatment, and outcome definitions, we had planned to perform a pooled analysis. We had intended to assess heterogeneity with the use of forest plots and by a formal statistical test for heterogeneity, i.e. the I² statistic. Substantial heterogeneity was defined as I² greater than 50% (Higgins 2011). We had planned to explore possible causes of heterogeneity, and take appropriate measures.

Assessment of reporting biases
If more than ten studies had been included in a meta-analysis, we had planned to construct a funnel plot to graphically ascertain the existence of publication bias (Higgins 2011).

Data synthesis
We had planned to enter data into the Cochrane software, Review Manager 2014, and analyse them according to the guidelines in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We had intended to use a fixed-effect model if we found no substantial heterogeneity, and a random-effects model if we found heterogeneity (I² greater than 50%).

Subgroup analysis and investigation of heterogeneity
We had planned to perform subgroup analysis based on systemic thrombolysis and catheter-directed thrombolysis, to determine the effect it may have had on outcome and possible heterogeneity between studies. We also had intended to examine heterogeneity for these by visual inspection of forest plots and the I² statistic.

Sensitivity analysis
We had planned to perform a sensitivity analysis by excluding studies that were at high risk of bias.

Summary of findings
We had planned to present the main findings of the review results concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the primary outcomes (Types of outcome measures) in a 'Summary of findings' table, according to the GRADE principles as described by Higgins 2011 and Atkins 2004. Since we had planned to assess different comparisons of interventions, we had planned to develop a 'Summary of findings' table for each comparison using the GRADEpro (GRADEproGDT) software to assist in the preparation of the 'Summary of findings' table.

R E S U L T S

Description of studies

Results of the search
See Figure 1
Figure 1. Study flow diagram.

- CENTRAL: 5175 reports identified
- WHO: 7 records for 7 trials found for thrombectomy and thrombosis
- ClinicalTrials.gov: 25 studies found for thrombectomy and thrombosis
- ISRCTN registry: 1 study found for thrombectomy and thrombosis
- 17 additional reports identified from the Specialised Register
- 6047 reports after duplicates removed, screened by CIS
  - 5040 assessed as not relevant for this review
  - 7 reports screened by authors
  - 2 studies (4 reports) excluded, with reasons:
    - 1 ongoing study
    - 1 awaiting classification
    - 1 not relevant
  - 7 full-text reports assessed for eligibility
  - 0 studies included in qualitative synthesis
  - 0 studies included in quantitative synthesis (meta-analysis)
Included studies
We found no randomised controlled trials that met the eligibility criteria for this review.

Excluded studies
See Characteristics of excluded studies
We excluded two studies. One study examined percutaneous aspiration thrombectomy versus medical treatment only (Cakir 2014), and the second study was not a randomised controlled trial (Srinivas 2014).

Ongoing studies and studies awaiting classification
We identified one eligible ongoing study (NCT02414802). This study is currently enrolling participants.
We identified one study that appeared to meet the inclusion criteria (TORPEDO 2012). However, on examination of the TORPEDO 2012 trial, it was clear that not all patients had an iliofemoral DVT, and not all were treated with pharmacomechanical thrombectomy. We contacted the authors of this trial to obtain the data on iliofemoral DVT patients stratified by pharmacomechanical thrombectomy, but to date, we have not had a response. If obtained, we hope to include this data in future updates of this review.

Risk of bias in included studies
As we identified no eligible completed studies, it was not possible to assess risk of bias.

Effects of interventions
We found no randomised controlled trials that met the eligibility criteria for this review.

DISCUSSION

Summary of main results
We found no randomised controlled trials investigating the effects of pharmacomechanical thrombectomy versus anticoagulation (alone or with compression stockings), mechanical thrombectomy, thrombolysis, or other endovascular techniques in the management of people with acute deep venous thrombosis (DVT) of the iliofemoral vein that met the eligibility criteria for this review.

Overall completeness and applicability of evidence
We found no randomised controlled trials that met the eligibility criteria for this review.
At present, there is a lack of randomised controlled trials on the effectiveness and safety of pharmacomechanical thrombectomy in the management of people with iliofemoral DVT.

Quality of the evidence
We found no randomised controlled trials that met the eligibility criteria for this review; therefore, we were unable to assess the quality of the evidence.

Potential biases in the review process
None of the review authors have any commercial or other conflict of interest. The Cochrane Vascular Information Specialist performed a comprehensive search of the literature, and review authors selected studies in accordance with recommendations provided in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We resolved disagreements by discussion.

Agreements and disagreements with other studies or reviews
To date, no other systematic review has examined pharmacomechanical thrombectomy for the management of people with acute DVT of the iliofemoral vein.
One study compared the effectiveness of catheter-directed thrombolysis in conjunction with assisted mechanical thrombolysis versus routine anticoagulation (unfractionated or low molecular weight heparin) in patients with a lower limb DVT (Srinivas 2014). The study was not included in this review as it was not randomised. Results showed that after six months, iliofemoral patency was found in 20 out of 25 patients (80%) in the intervention group versus seven out of 26 patients (23%) treated with anticoagulation alone (P < 0.01). Post-thrombotic syndrome was diagnosed in 5 patients (20%) in the intervention group versus 19 (77%) in the anticoagulation alone group (P < 0.01). Pulmonary embolism occurred in 4 patients (15%) in the intervention group versus 6 (21%) of the patients who received anticoagulation. Death due to pulmonary embolism occurred in two patients in each treatment group. In the intervention group, 4 patients (15%) also developed anaemia, and required a blood transfusion. There was no difference in prolonged hospital stay between the catheter-directed
thrombolysis in conjunction with assisted mechanical thrombolysis group (mean 5 days, standard deviation (SD) 1.3 days) and the routine anticoagulation arm (mean 4.8 days, SD 1.4 days).

A recent review discussed the three main types of pharmacomechanical thrombectomy devices (rotating motorised systems, rheolytic instruments and ultrasound enhanced devices; Blackwood 2016). The devices were compared for success rate, clinical patency at follow-up, and complications, based on 3077 participants in seven studies. The studies varied in size from 40 to 2204 participants. Patency rates varied from 65% to 98%, major bleeding complications ranged from 0% to 11%, and the rate of post-thrombotic syndrome ranged from 3% to 48%. However, the quality of the studies was extremely varied. Only two randomised controlled trials were included, only one of which appeared to meet the inclusion criteria for this review (TORPEDO 2012). However, on examination of the TORPEDO 2012 trial, it was clear that not all patients had an iliofemoral DVT, and not all were treated with pharmacomechanical thrombectomy. We contacted the authors of this trial to obtain the data on iliofemoral DVT patients stratified by pharmacomechanical thrombectomy but, to date, we have not had a response. If obtained, we hope to include this data in future updates of this review.

**Authors’ conclusions**

**Implications for practice**

There is insufficient evidence to draw any conclusions about effectiveness and safety of pharmacomechanical thrombectomy versus anticoagulation (alone or with compression stockings), mechanical thrombectomy, thrombolysis, or other endovascular techniques in the management of people with acute deep venous thrombosis of the iliofemoral vein, because no randomised trials were eligible for inclusion in this review.

**Implications for research**

This review highlights the gap in evidence for the use of pharmacomechanical thrombectomy for acute deep venous thrombosis (DVT) of the iliofemoral vein. Future randomised controlled trials are required. Future studies should also aim to incorporate the Lower Extremity Thrombosis (LET) score (Strijkers 2015), a relatively new classification system designed to identify patients at high risk for developing post-thrombotic syndrome in the acute DVT phase, using thrombus location and extent.

**Acknowledgements**

We would like to thank the Cochrane Vascular Information Specialist for assistance with search strategies.

**References**

References to studies excluded from this review

Cakir 2014  *(published data only)*


Srinivas 2014  *(published and unpublished data)*


References to ongoing studies

NCT02414802  *(published data only)*


Additional references

Access Economics Pty Limited 2008

Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis (Review)

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Turpie 1990

Watson 2014

White 2003

References to other published versions of this review
Robertson 2015

* Indicates the major publication for the study
Characteristics of excluded studies  [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cakir 2014</td>
<td>Study examined percutaneous aspiration thrombectomy versus medical treatment only</td>
</tr>
<tr>
<td>Srinivas 2014</td>
<td>Study was not a randomised trial (personal communication with the author)</td>
</tr>
</tbody>
</table>

Characteristics of studies awaiting assessment  [ordered by study ID]

TORPEDO 2012

Methods
- Study design: randomised controlled trial

Participants
- Setting: hospital
- Country: United States of America
- Inclusion criteria: adult patients with symptomatic DVT, involving popliteal vein or more proximal venous segments, diagnosed by venous duplex sonography or multislice CT venography. The affected veins were divided into five segments, based on the anatomical involvement of DVT: inferior vena cava (IVC), right and left iliac veins, and right and left femoropopliteal veins
- Exclusion criteria: patients were excluded if they had serious bleeding in the previous 4 weeks, contra-indication to unfractionated or low-molecular weight heparin, or severe thrombocytopenia (platelet count of < 30,000/mm³)

Interventions
- Intervention 1: PEVI + anticoagulation. For acute DVT with otherwise preserved venous anatomy, thrombectomy was performed using any of the following: Angiojet DVX catheter (Medrad/Possis, Warrendale, PA), Trellis device (Bacchus Vascular, Santa Clara, CA), or manual aspiration with an 8-F guide catheter. No preference was given to any thrombectomy device, and its use was based on operator discretion and device availability. For severe ‘venosclerotic’ disease with distorted anatomy, a venous conduit was created using balloon venoplasty and stents. If residual thrombus was more than 30% of the luminal area, an infusion catheter was placed and low-dose thrombolytic therapy with tissue plasminogen activator (tPA) at 1 mg/hr delivered for 20 to 24 hr. In this scenario, the patient was brought back to the angiography suite for re-evaluation after tPA administration
- Intervention 2: anticoagulation alone. Initial anticoagulation therapy consisted of subcutaneous enoxaparin at 1 mg/kg twice daily, administered subcutaneously. For those with renal insufficiency or concomitant massive PE, unfractionated heparin (UFH) was started at 80 IU/kg intravenously as loading dose, followed by 18 IU/hr, with subsequent adjustments to keep the activated partial thromboplastin time 1.5 to 2 times the baseline level. Warfarin was initiated on admission

Outcomes
- Primary: post-thrombotic syndrome and recurrence of VTE at 6 months
- Secondary: bleeding, duration of hospitalisation, reduction of leg oedema, reduction of skin induration, and patient’s subjective perception of improvement

Notes
- Authors were contacted for data on participants with iliofemoral DVT and for data stratified by pharmacomechanical thrombectomy. To date, no response has been received

CT: computed tomography
Characteristics of ongoing studies  *(ordered by study ID)*

**NCT02414802**

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>Study on the application of a novel aspiration thrombectomy device combined with catheter-directed thrombolysis for the treatment of acute iliofemoral deep venous thrombosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Study design: randomised, parallel assignment study</td>
</tr>
</tbody>
</table>
| Participants        | Setting: hospital  
|                     | Country: China  
|                     | Inclusion criteria:  
|                     | • clinical diagnosis of iliofemoral deep venous thrombosis  
|                     | • symptoms of less than 14 days’ duration  
|                     | • good function status  
|                     | • a life expectancy of more than 1 year  
|                     | • a low risk of bleeding  
|                     | Exclusion criteria:  
|                     | • without iliac vein thrombosis  
|                     | • anticoagulation or thrombolysis contraindications, or both  
|                     | • systemic infection  
|                     | • heart, hepatic, renal function insufficiency |
| Interventions       | Intervention 1: combined thrombectomy device. A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis. Ten million U of urokinase once every 4 to 6 hours will be used during catheter-directed thrombolysis therapy. Anticoagulation therapy will be administered via subcutaneous injection of low molecular weight heparin calcium (LMWH-Ca 5000 U/12 h) at discharge  
|                     | Intervention 2: participants will undergo catheter-directed thrombolysis alone. A total of 100,000 units urokinase will be pulse-spray injected through the catheter once every 4 to 6 hours. Anticoagulation therapy will be administered via subcutaneous injection of LMWH-Ca 5000 U/12 h at discharge |
| Outcomes            | Primary: patency of lower extremity deep venous system  
|                     | Secondary: technical success rate, thrombus removal rate, complications, blood loss, improvement of clinical symptoms and signs and incidence of post-thrombotic syndrome |
| Starting date       | December 2014 |
| Contact information | Qingqiao Zhang, Xuzhou Medical College |

 Notes  

LMWH-Ca: low molecular weight heparin calcium
APPENDICES

Appendix 1. CENTRAL search strategy

<table>
<thead>
<tr>
<th>#</th>
<th>MESH DESCRIPTOR</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>MESH DESCRIPTOR Thrombosis</td>
<td>1231</td>
</tr>
<tr>
<td>#2</td>
<td>MESH DESCRIPTOR Thromboembolism</td>
<td>892</td>
</tr>
<tr>
<td>#3</td>
<td>MESH DESCRIPTOR Venous Thromboembolism</td>
<td>233</td>
</tr>
<tr>
<td>#4</td>
<td>MESH DESCRIPTOR Venous Thrombosis EXPLODE ALL TREES</td>
<td>1996</td>
</tr>
<tr>
<td>#5</td>
<td>(thrombus* or thrombopro* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or embol*):TI,AB,KY</td>
<td>16760</td>
</tr>
<tr>
<td>#6</td>
<td>MESH DESCRIPTOR Pulmonary Embolism EXPLODE ALL TREES</td>
<td>729</td>
</tr>
<tr>
<td>#7</td>
<td>(PE or DVT or VTE):TI,AB,KY</td>
<td>4422</td>
</tr>
<tr>
<td>#8</td>
<td>((vein* or ven*) near thromb*):TI,AB,KY</td>
<td>6043</td>
</tr>
<tr>
<td>#9</td>
<td>(blood near3 clot*):TI,AB,KY</td>
<td>2424</td>
</tr>
<tr>
<td>#10</td>
<td>(pulmonary near3 clot*):TI,AB,KY</td>
<td>5</td>
</tr>
<tr>
<td>#11</td>
<td>(lung near3 clot*):TI,AB,KY</td>
<td>4</td>
</tr>
<tr>
<td>#12</td>
<td>#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11</td>
<td>21706</td>
</tr>
<tr>
<td>#13</td>
<td>MESH DESCRIPTOR Thrombectomy EXPLODE ALL TREES</td>
<td>143</td>
</tr>
<tr>
<td>#14</td>
<td>(percutaneous near2 endovascular):TI,AB,KY</td>
<td>13</td>
</tr>
<tr>
<td>#15</td>
<td>PEVI:TI,AB,KY</td>
<td>4</td>
</tr>
<tr>
<td>#16</td>
<td>thrombecto*:TI,AB,KY</td>
<td>428</td>
</tr>
<tr>
<td>#17</td>
<td>excis*</td>
<td>3652</td>
</tr>
</tbody>
</table>
(Continued)

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>#18</td>
<td>suction:TLAB,KY</td>
<td>1970</td>
</tr>
<tr>
<td>#19</td>
<td>aspiration or thromboaspirat*</td>
<td>3693</td>
</tr>
<tr>
<td>#20</td>
<td>angiojet:TLAB,KY</td>
<td>10</td>
</tr>
<tr>
<td>#21</td>
<td>jet*:TLAB,KY</td>
<td>756</td>
</tr>
<tr>
<td>#22</td>
<td>pharmaco*:TLAB,KY</td>
<td>122292</td>
</tr>
<tr>
<td>#23</td>
<td>mechanical*:TLAB,KY</td>
<td>11751</td>
</tr>
<tr>
<td>#24</td>
<td>(Terotola OR Rotarex or Aspirex):TLAB,KY</td>
<td>3</td>
</tr>
<tr>
<td>#25</td>
<td>(amplatz OR angiovac):TLAB,KY</td>
<td>26</td>
</tr>
<tr>
<td>#26</td>
<td>rotat*:TLAB,KY</td>
<td>4215</td>
</tr>
<tr>
<td>#27</td>
<td>rheoly*:TLAB,KY</td>
<td>26</td>
</tr>
<tr>
<td>#28</td>
<td>ultrasound:TLAB,KY</td>
<td>11469</td>
</tr>
<tr>
<td>#29</td>
<td>Endowave:TLAB,KY</td>
<td>0</td>
</tr>
<tr>
<td>#30</td>
<td>(power near2 pulse):TLAB,KY</td>
<td>20</td>
</tr>
<tr>
<td>#31</td>
<td>#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30</td>
<td>154857</td>
</tr>
</tbody>
</table>

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>#32</td>
<td>#12 AND #31</td>
</tr>
</tbody>
</table>

**Contributions of Authors**

LR: drafted the protocol, selected studies for inclusion and wrote the review

OM: contributed to the protocol, selected studies for inclusion, and provided clinical input to the review

AB: drafted the protocol, selected studies for inclusion
DECLARATIONS OF INTEREST

LR: none known
OM: none known
AD: none known

SOURCES OF SUPPORT

Internal sources
- No sources of support supplied

External sources
- National Institute for Health Research (NIHR), UK.
  This project was supported by the NIHR, via Cochrane Programme Grant funding (13/89/23) to Cochrane Vascular. The views and opinions expressed therein are those of the review authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.
- Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government, UK.
The Cochrane Vascular editorial base is supported by the Chief Scientist Office.

INDEX TERMS

Medical Subject Headings (MeSH)
- Catheterization, Peripheral; *Endovascular Procedures; *Femoral Vein; *Iliac Vein; Thrombectomy [*methods]; Venous Thrombosis [*therapy]

MeSH check words
- Adult; Humans